Danaher Corporation
Danaher Corporation

A Beacon for CRISPR Cures: Danaher Life Sciences Monthly Newsletter

To view this email as a web page, click here

 
Your Monthly Briefing
February 2024
 
 
Last month, Danaher Corporation and the
Innovative Genomics Institute announced
a historic partnership to create a scalable
gene-editing platform technology for rare
and other diseases.
 
 
 
 
 
“What we need is a blueprint”
 
 
 
 
 
The Danaher-IGI Beacon for CRISPR Cures aims to develop gene-editing therapies for two genetic disorders related to inborn errors of immunity (IEIs). The goal is to develop a scalable platform approach that enables new a new medicine to be rapidly built, even beyond IEIs.
 
 
  • Learn how Danaher and IGI are approaching this together: Read the press release
  • Watch Danaher CEO Rainer Blair and IGI Founder Jennifer Doudna introduce the Beacon: see the video
 
 
 
 
 
The Value of Partnership
 
 
 
 
Developing groundbreaking new biologics is difficult. The long development time, need for scientific innovations, and regulatory requirements necessitate partnership to achieve mutual goals.
 
 
  • From our CTO of Genomic Medicines: Why collaboration is key to advancing cell and gene therapy: article here
  • Read how the Life Sciences companies of Danaher can help: our roadmap to accelerate drug development. Why partnership?
 
 
 
 
 
See the breadth of the Danaher Life Sciences portfolio
 
 
 
 
 
See what’s possible with us: an interactive overview of the Danaher Life Sciences portfolio: Access here.
 
 
 
 
 
 
 
 
Our portfolio of brands produces to steady stream of high-impact innovations accross all product lines.
 
 
We continously enhance our product portfolio through organic investments and strategic acquisitions.
 
 
 
As a result, we have one of the world's largest teams of dedicated customer-facing subject matter experts, who are passionate about supporting our customers.
 
 
Access to our Strategic Partner Concierge Desk.  Get complementary access expedited support via [email protected] and get a response in 4 business hours.
 
 
 
 
 
 
About Danaher Life Sciences
 
 
Every day, scientists around the world are working to understand the causes of disease, develop new therapies and vaccines and test new drugs. Danaher Life Sciences, a group of businesses at Danaher Corporation, make this leading-edge scientific research possible. Our capabilities extend beyond research to power the creation of biopharmaceuticals, cell and gene therapies and other breakthrough treatments to advance patient health and improve treatment outcomes.
 
 
 
 
 
 
 
 
 
About Danaher
 
 
 
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 81,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
 
 
 
 
 
 
 
 

© 2024 DH Life Sciences LLC. All marks and logos referenced herein are property of their respective owners
® indicates a trademark registered in the USA
DH Life Sciences LLC, 500 Old Connecticut Path, Framingham, MA 01701
lifesciences.danaher.com
 

This email was sent to [email protected]. If you no longer wish to receive these emails you may unsubscribe at any time.

Prev Newsletter Next Newsletter